Alnylam Pharmaceuticals (ALNY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.21
- EPS estimate
- $1.63
- EPS surprise
- −25.78%
- Revenue surprise
- −2.36%
- Revenue
- $1.3B
- Revenue estimate
- $1.3B
- Reported
- Jul 30, 2026
Alnylam Pharmaceuticals reported Q2 2026 results on July 30, 2026. Earnings per share were $1.21, missing the $1.63 estimate by 25.78%. Revenue was $1.3 billion, in line with the consensus and the highest in the table. Revenue rose about 68% from $773.7 million in Q2 2025, when Alnylam posted a loss of $0.51 per share.
The table shows a shift from losses to profits. Fifteen of the 20 quarters were losses, the deepest $3.32 per share in Q3 2022. The annual loss narrowed from $9.29 per share in 2022 to $3.56 in 2023 and $2.17 in 2024, and 2025 ended with a profit of $1.71. Apart from Q3 2023, at $1.15, profits began in Q3 2025 and have held for four straight quarters. Annual revenue rose from about $1.04 billion in 2022 to about $3.67 billion in 2025. Against estimates there were 11 beats and 9 misses, alternating in the last four quarters.
Alnylam has reported Q3 results between October 27 and November 2 in each of the past five years, which points to late October or early November 2026. The next report will show whether profits continue for a fifth straight quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $1.63 | $1.21 | −25.78% | $1.3B | SEC |
| Q1 2026 | Apr 30, 2026 | $0.90 | $1.51 | +68.72% | $1.2B | SEC |
| Q4 2025 | Feb 12, 2026 | $1.16 | $0.82 | −29.06% | $1.1B | SEC |
| Q3 2025 | Oct 30, 2025 | $0.56 | $1.84 | +227.99% | $1.2B | SEC |
| Q2 2025 | Jul 31, 2025 | −$0.54 | −$0.51 | +6.20% | $773.7M | SEC |
| Q1 2025 | May 1, 2025 | −$0.89 | −$0.44 | +50.56% | $594.2M | SEC |
| Q4 2024 | Feb 13, 2025 | −$0.59 | −$0.65 | −9.78% | $593.2M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.92 | −$0.87 | +5.08% | $500.9M | SEC |
| Q2 2024 | Aug 1, 2024 | −$1.07 | −$0.13 | +87.82% | $659.8M | SEC |
| Q1 2024 | May 2, 2024 | −$1.12 | −$0.52 | +53.41% | $494.3M | SEC |
| Q4 2023 | Feb 15, 2024 | −$1.19 | −$1.10 | +7.28% | $439.7M | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.45 | $1.15 | +179.55% | $750.5M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.51 | −$2.21 | −46.76% | $318.8M | SEC |
| Q1 2023 | May 4, 2023 | −$1.67 | −$1.40 | +16.19% | $319.3M | SEC |
| Q4 2022 | Feb 23, 2023 | −$1.86 | −$1.68 | +9.64% | $335.0M | SEC |
| Q3 2022 | Oct 27, 2022 | −$1.74 | −$3.32 | −90.48% | $264.3M | — |
| Q2 2022 | Jul 28, 2022 | −$1.59 | −$2.29 | −44.47% | $224.8M | — |
| Q1 2022 | Apr 28, 2022 | −$1.81 | −$2.00 | −10.58% | $213.3M | — |
| Q4 2021 | Feb 10, 2022 | −$1.55 | −$2.16 | −39.70% | $258.5M | — |
| Q3 2021 | Oct 28, 2021 | −$1.54 | −$1.72 | −11.91% | $187.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Alnylam Pharmaceuticals (ALNY) last report earnings?
Alnylam Pharmaceuticals last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did ALNY beat earnings estimates?
No. Alnylam Pharmaceuticals reported EPS of $1.21 for Q2 2026 against a $1.63 estimate — a 25.78% miss.
How much revenue did ALNY report last quarter?
Alnylam Pharmaceuticals reported $1.3B in revenue for Q2 2026, against a consensus estimate of $1.3B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.